Financial PerformanceReturn to growth, solid margin expansion, healthy free cash flow, and leverage moving below 3x are positives for Avantor.
Market ConditionsBioscience Production segment returned to growth, driven by strong order intake expected to generate momentum into 2025.
ValuationValuation is not demanding with a ~25% discount to peers, and downside from here is likely limited.